Editas Medicine, Inc. (EDIT) Social Stream



Editas Medicine, Inc. (EDIT): $12.59

0.76 (+6.42%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add EDIT to Watchlist
Sign Up

Industry: Biotech


Ranked

of 399

in industry

Editas Medicine Inc (EDIT) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering EDIT.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-09 13 $80 $30 $54.909 $19.02 188.69%
2022-01-06 12 $80 $24 $52.2 $19.02 174.45%
2022-01-31 12 $80 $16 $51.4 $19.02 170.24%
2022-02-25 12 $80 $16 $46.4 $19.02 143.95%
2022-02-28 11 $80 $16 $41.777 $19.02 119.65%

The Trend in the Analyst Price Target


EDIT's average price target has moved up $6.32 over the prior 22 months.

Over the past 47 weeks, EDIT's average upside potential has been 43.49%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-13 14 81 20 44.640 37.42 19.29%
2021-08-28 15 81 23 50.830 65.53 -22.43%
2021-11-09 13 80 30 53.500 40.56 31.9%
2021-11-09 13 80 30 54.909 40.56 35.38%
2022-01-31 12 80 16 51.400 19.04 169.96%

EDIT Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.39 5 0 4 2 2 11

The Trend in the Broker Recommendations


Over the past 21 months, EDIT's average broker recommendation rating worsened by 0.28.

The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.

  • To contextualize these metrics, consider that out of all US stocks, Editas Medicine Inc's variance in analysts' estimates is lower than -751.65% of them.
  • Editas Medicine Inc's number of analysts covering the stock is greater than 817% of stocks in the mid market cap category.
  • To contextualize these metrics, consider that out of stocks in the mid market cap category, Editas Medicine Inc's upside potential (average analyst target price relative to current price) is higher than 783.3% of them.
  • In terms of how Editas Medicine Inc fares relative to Pharmaceutical Products stocks, note that its average analyst price target is higher than 611.1% of that group.

Stocks similar to Editas Medicine Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are CRTX, CCCC, and BEAM.

Make investment decisions regarding EDIT using the data that counts. Try POWR Ratings for free.


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.3174 seconds.